Our studies provide novel insights into the biology of MLL-fusion proteins and identify an unexpected dependency of MLL-fusion-expressing leukemia cells on the methyltransferase SETD2 during leukemia initiation and maintenance, validating SETD2 as an actionable target MLL-rearranged leukemia. This evidence concerns the gene KMT2A and leukemia.